Dyslipidaemia and statin use in individuals aged 10 to <40 years in the T1D Exchange clinic registry. Issue 1 (16th August 2018)

• Record Type: Journal Article
• Authors: Lyons, Sarah K.; Boyle, Claire T.; DeSalvo, Daniel J.; Rickels, Michael R.; Wood Heickman, Lauren K.; Miller, Kellee M.; Foster, Nicole C.; Clements, Mark A.
• Is Part Of: Diabetes, obesity & metabolism. Volume 21:Issue 1(2019)
• Page Start: 170
• Page End: 172
• Publication Date: 2018-08-16
• Subjects: dyslipidaemia -- type 1 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13475
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : For individuals aged 10 to <40 years with type 1 diabetes and dyslipidaemia, US national guidelines recommend consideration of statin therapy based on age, low‐density lipoprotein cholesterol (LDL‐C) level and other cardiovascular risk factors. We evaluated dyslipidaemia prevalence, statin therapy use, and associations between not meeting target LDL‐C [<100 mg/dL (<5.55 mmol/L)] and other cardiovascular disease (CVD) risk factors in individuals aged 10 to <40 years in the T1D Exchange clinic registry. In 7223 participants, statin use was 2% in 10 to <18 year olds, 4% in 18 to <25 year olds, and 21% in 25 to <40 year olds. Individuals not on statin therapy with LDL‐C above target were more likely to have ≥1 additional CVD risk factor(s) than those with LDL‐C in the target range for all age groups (all P < 0.01). While most individuals not on statin therapy had LDL‐C in the target range, those who did not were more likely to have ≥1 additional CVD risk factor(s), and therefore longitudinal study of lipid levels and statin use is needed to see if treatment of dyslipidaemia to target LDL‐C levels may lower the risk of future CVD in individuals aged 10 to <40 years with type 1 diabetes.